New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
Children with relapsed, recurrent or metastatic sarcomas represent a therapeutic challenge for the pediatric oncologist. Strategies for the development of newer therapies for children with these sarcomas have, in the past, been histology-specific. For example, drug development in rhabdomyosarcoma has relied upon the preclinical xenograft model, whereas therapies for pediatric nonrhabdomyosarcomatous soft tissue sarcomas have mostly been derived from adult trials. The progress to date and the tools used in the treatment of advanced pediatric sarcomas will be summarized in this review.
Gupta
Abha A
AA
Hospital for Sick Children, Division of Hematology Oncology, Toronto, Canada. abha.gupta@sickkids.ca
Pappo
Alberto S
AS
D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D004195:Disease Models, Animal; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy* / Q000556:secondary*; D015996:Survival Rate; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D019772:Topotecan; D002166:Camptothecin